Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Auranofin: Precision Thioredoxin Reductase Inhibitor for ...

    2026-01-26

    Auranofin: Precision Thioredoxin Reductase Inhibitor for Cancer and Infection Research

    Overview: Principle and Mechanism of Auranofin

    Auranofin (SKU: B7687), available through APExBIO, is a potent small molecule TrxR inhibitor that has redefined experimental approaches in oncology, redox biology, and infectious disease research. By selectively targeting thioredoxin reductase (TrxR)—a critical flavoenzyme facilitating electron transfer from NADPH to thioredoxin—Auranofin disrupts cellular redox homeostasis, induces oxidative stress, and triggers apoptosis via caspase signaling pathways. This multifaceted mechanism positions Auranofin as a versatile tool for both in vitro and in vivo studies.

    Key quantitative features include:

    • IC50 for TrxR inhibition: ~88 nM
    • Anti-Helicobacter pylori activity: Inhibition at ~1.2 μM
    • Radiosensitization in tumor models: Effective at 3–10 μM in murine 4T1 and EMT6 cells, with in vivo synergy at 3 mg/kg
    • PC3 human prostate cancer cell viability: IC50 ≈ 2.5 μM after 24 hours

    As a radiosensitizer for tumor cells and an antimicrobial agent against Helicobacter pylori, Auranofin's ability to induce apoptosis via caspase activation and modulate oxidative stress expands its utility across a wide spectrum of experimental models. Recent studies—including the landmark work on cytoskeleton-dependent autophagy (Liu et al., 2024)—further highlight the interplay between redox disruption and mechanotransduction in the context of cellular stress responses.

    Experimental Workflow: Step-by-Step Protocol Enhancements

    Preparation and Solubility

    • Solvents: Dissolve Auranofin in DMSO (≥67.8 mg/mL) or ethanol (≥31.6 mg/mL). Note that the compound is insoluble in water.
    • Storage: Store the solid form at room temperature. Prepare fresh solutions prior to each experiment and avoid long-term storage of aliquots to preserve activity.

    Cell-Based Assays

    1. Cell line selection: Auranofin is validated in a range of models, including PC3 (prostate cancer), 4T1 and EMT6 (murine breast cancer), and H. pylori infection systems.
    2. Dosing: For apoptosis and redox studies, treat cells with a dose range of 3.125–100 μM. In PC3 cells, significant inhibition of viability is observed at an IC50 of 2.5 μM after 24 hours.
    3. Assays: Assess cell viability (e.g., MTT or CellTiter-Glo), apoptosis (Annexin V/PI, caspase-3/8 activation), and ROS generation (DCFDA or MitoSOX).
    4. Radiosensitization: For combined therapy, pre-treat tumor cells with 3–10 μM Auranofin before irradiation, then analyze clonogenic survival or apoptosis markers.

    In Vivo Protocols

    • Tumor models: In 4T1 tumor-bearing mice, subcutaneous administration of Auranofin at 3 mg/kg, especially in combination with buthionine sulfoximine, enhances radiosensitivity and prolongs survival.
    • Monitoring: Track tumor volume, animal weight, and survival rates. Collect tissue samples for histology and oxidative stress marker analysis.

    Autophagy and Cytoskeletal Studies

    Building on the insights from Liu et al., 2024, researchers can combine Auranofin treatment with mechanical or pharmacologic modulation of the cytoskeleton to study how redox imbalance intersects with autophagy. Employ fluorescent labeling, western blotting for LC3-II/p62, and cytoskeletal inhibitors or activators to dissect the mechanotransduction-autophagy axis.

    Advanced Applications and Comparative Advantages

    Cancer Research and Radiosensitization

    Auranofin stands out as a radiosensitizer for tumor cells due to its ability to disrupt redox homeostasis and amplify oxidative stress. By downregulating anti-apoptotic proteins (Bcl-2, Bcl-xL) and activating caspase-3/8, it enhances mitochondrial apoptosis following irradiation, leading to improved tumor control in both cell culture and animal models.

    In comparison to conventional radiosensitizers, Auranofin’s dual action—as a potent oxidative stress modulator and apoptosis inducer—yields synergistic effects, as documented in "Harnessing Redox Disruption and Cytoskeletal Autophagy". This article complements the current workflow by detailing how cytoskeleton-dependent autophagy can be leveraged alongside redox manipulation for maximal therapeutic effect.

    Antimicrobial Activity Against Helicobacter pylori

    With an effective concentration of ~1.2 μM, Auranofin inhibits H. pylori growth, making it a valuable tool for antimicrobial drug screening and mechanistic studies. Compared to broad-spectrum antibiotics, its mechanism—targeting TrxR and disrupting bacterial redox balance—offers specificity and a distinct mode of action, as further explored in "Precision Redox Disruption for Reliable Data". This resource contrasts Auranofin’s reproducibility and efficacy in antimicrobial workflows with traditional approaches.

    Integrative Redox and Autophagy Research

    Auranofin’s capacity to bridge redox homeostasis disruption with apoptosis and autophagy modulation is highlighted in "Precision TrxR Inhibitor for Redox and Apoptosis". Here, the focus extends to the modulation of cytoskeleton-dependent autophagy—a process increasingly recognized for its role in cancer cell survival and response to therapy. The interplay between mechanotransduction, cytoskeletal dynamics, and redox signaling, as established in Liu et al., 2024, positions Auranofin as a linchpin for multidimensional experimental designs.

    Troubleshooting and Optimization Tips

    • Solution stability: Prepare Auranofin solutions fresh for each experiment. Avoid repeated freeze-thaw cycles and long-term storage in solvents to prevent degradation.
    • Solvent compatibility: Ensure complete dissolution in DMSO or ethanol before dilution into culture medium. Maintain final DMSO/ethanol concentration below 0.1% in cell-based assays to minimize cytotoxicity from the vehicle.
    • Dosage calibration: Start with a broad range (3.125–100 μM) to determine cell line-specific sensitivity. For apoptosis assays, focus on concentrations around the reported IC50 (e.g., 2.5 μM for PC3 cells) for maximal signal-to-noise ratio.
    • Control experiments: Include untreated, vehicle, and positive control groups (e.g., known TrxR inhibitors or ROS inducers) to validate specificity.
    • Assay timing: For radiosensitization, pre-treat cells for 2–4 hours before irradiation. For apoptosis and ROS assays, 24-hour exposure is optimal based on published data.
    • Autophagy assays: When combining with cytoskeletal modulators, titrate concentrations to avoid off-target effects and confirm autophagic flux using LC3-II/p62 markers.

    Future Outlook: Unlocking New Experimental Paradigms

    The integration of Auranofin into redox, autophagy, and mechanobiology workflows is poised to accelerate translational discoveries in both oncology and infectious disease. The recent demonstration that cytoskeleton dynamics regulate mechanical stress-induced autophagy (Liu et al., 2024) opens new avenues for combinatorial studies, where precise redox disruption by Auranofin can be correlated with mechanical and cytoskeletal cues.

    Emerging directions include:

    • High-content phenotypic screening: Leveraging Auranofin’s multidimensional activity profile in automated imaging and omics workflows.
    • Mechanotransduction-cancer therapy cross-talk: Systematic mapping of how redox disruption intersects with force-induced autophagic responses.
    • Personalized radiosensitization strategies: Tailoring Auranofin dosing and scheduling to tumor genotype and microenvironment features.
    • Expanding antimicrobial repertoire: Exploring synergistic combinations of Auranofin with established antibiotics for resistant H. pylori strains.

    For an in-depth discussion of Auranofin’s translational impact and protocol optimization, see the integrative review "Auranofin as a Precision Tool: Targeting TrxR for Integrated Research", which extends the current narrative by connecting molecular mechanisms to practical experimental innovations.

    In conclusion, Auranofin from APExBIO offers researchers an unparalleled combination of specificity, reproducibility, and translational relevance for apoptosis induction via caspase activation, oxidative stress modulation, and redox homeostasis disruption in cancer and infection models. By aligning rigorous protocol design with emerging insights from mechanobiology and cytoskeletal autophagy, investigators can unlock the full experimental potential of this gold-standard thioredoxin reductase inhibitor.